CRISPR Therapeutics AG (CRSP) Accumulated Depreciation & Amortization (2016 - 2025)
Historic Accumulated Depreciation & Amortization for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to $85.6 million.
- CRISPR Therapeutics AG's Accumulated Depreciation & Amortization rose 2628.96% to $85.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $85.6 million, marking a year-over-year increase of 2628.96%. This contributed to the annual value of $72.3 million for FY2024, which is 3525.72% up from last year.
- According to the latest figures from Q3 2025, CRISPR Therapeutics AG's Accumulated Depreciation & Amortization is $85.6 million, which was up 2628.96% from $81.6 million recorded in Q2 2025.
- In the past 5 years, CRISPR Therapeutics AG's Accumulated Depreciation & Amortization ranged from a high of $85.6 million in Q3 2025 and a low of $23.9 million during Q1 2021
- Moreover, its 5-year median value for Accumulated Depreciation & Amortization was $48.5 million (2023), whereas its average is $51.0 million.
- Within the past 5 years, the most significant YoY rise in CRISPR Therapeutics AG's Accumulated Depreciation & Amortization was 8566.65% (2022), while the steepest drop was 1479.92% (2022).
- CRISPR Therapeutics AG's Accumulated Depreciation & Amortization (Quarter) stood at $37.8 million in 2021, then decreased by 10.51% to $33.8 million in 2022, then surged by 57.94% to $53.4 million in 2023, then skyrocketed by 35.26% to $72.3 million in 2024, then increased by 18.46% to $85.6 million in 2025.
- Its Accumulated Depreciation & Amortization stands at $85.6 million for Q3 2025, versus $81.6 million for Q2 2025 and $77.0 million for Q1 2025.